Full View

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H Farkas, M Stobiecki, J Peter… - Clinical and …, 2021 - Wiley Online Library
Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …
被引用次数：30 相关文章

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H Farkas, M Stobiecki, P Jonny… - Clinical and …, 2021 - search.proquest.com
Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.

H Farkas, M Stobiecki, J Peter, T Kinaciyan… - Clinical and …, 2021 - europepmc.org
Background Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …
[HTML] nih.gov

[HTML][HTML] Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H Farkas, M Stobiecki, J Peter, T Kinaciyan… - Clinical and …, 2021 - ncbi.nlm.nih.gov
Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study

H Farkas, M Stobiecki, J Peter… - Clinical and …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study.

H Farkas, M Stobiecki, J Peter… - Clinical & …, 2021 - search.ebscohost.com
Abstract Background: Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma
kallikrein recently approved for prevention of angioedema attacks in adults and adolescents …

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H Farkas, M Stobiecki, J Peter, T Kinaciyan… - Clinical and …, 2021 - zora.uzh.ch
Background: Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H Farkas, M Stobiecki, J Peter, T Kinaciyan, M Maurer… - 2021 - Wiley Online Library
Abstract Background: Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma
kallikrein recently approved for prevention of angioedema attacks in adults and adolescents …

[引用][C] Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study

H Farkas, M Stobiecki, J Peter, T Kinaciyan, M Maurer… - 2021 - ruj.uj.edu.pl
[PDF] archive.org

[PDF][PDF] Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H Farkas, M Stobiecki, J Peter, T Kinaciyan, M Maurer… - 2021 - scholar.archive.org
Abstract Background: Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma
kallikrein recently approved for prevention of angioedema attacks in adults and adolescents …